GT Biopharma, Inc. Share Price & Technical Analysis
GTBP · $0.39 (-11.36%)
Healthcare / Biotechnology
$0.39
-11.36%
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that…
Price chart
Seasonality
May has 4 positive and 1 negative years (last 5 years shown)
33% return in May, -9% avg return in past 3 year May month.
-41% return in 2026, -99% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -12% | -17% | -20% | -25% | 33% | – | – | – | – | – | – | – | -41% |
| 25 | -27% | 9% | -8% | 9% | 8% | 33% | -47% | -50% | -33% | 0% | 33% | 0% | -72% |
| 24 | -25% | -32% | 5% | -35% | 9% | -26% | -7% | -19% | 5% | 26% | -7% | 0% | -107% |
| 23 | -14% | -14% | -18% | -34% | -43% | 21% | -10% | -5% | -8% | 4% | -8% | 13% | -117% |
| 22 | 4% | 2% | -9% | -28% | 31% | 6% | -2% | -9% | -32% | 5% | -11% | -44% | -88% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Downtrend · Uptrend
GT Biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of immuno-oncology products based on its Tri-specific Killer Engager (TriKE) and Tetra-specific Killer Engager (Dual Targeting TriKE) platforms. It develops GTB-3650, which is in phase 1 trials that target CD33 on the surface of myeloid leukemias and an agonistic camelid; GTB-5550, that is in phase 1 dose escalation basket trial that targets B7-H3 on the surface of advanced solid tumors;and GTB-7550, a pre-clinical stage product candidate in development for the treatment of lupus and other autoimmune disorders. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in San Francisco, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$11.27M
P/E ratio
—
52W high
$3.85
52W low
$0.26
Volume
14,77,128
Beta
0.64
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is GT Biopharma, Inc. share price today?
- GT Biopharma, Inc. (GTBP) last traded around $0.39 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does GTBP have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for GTBP. Download the app for real-time alerts.
- How can I analyze GT Biopharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.